Article Abstract

First-line pembrolizumab in programmed death ligand 1 positive non-small cell lung cancer

Authors: Camille Travert, Pascale Tomasini, Arnaud Jeanson, Laurent Greillier, Fabrice Barlesi


In these past few years, immune checkpoint inhibitors (ICI) in locally advanced or metastatic non-small cell lung cancer (NSCLC) have fundamentally changed the prognosis for some patients.